Dennis A Hesselink

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, and Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus MC
    Clin Pharmacol Ther 78:317-21. 2005
  2. doi CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus MC, Rotterdam, The Netherlands
    Pharmacogenet Genomics 18:339-48. 2008
  3. doi The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation
    Dennis A Hesselink
    Division of Nephrology and Renal Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Room D 427, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Clin Pharmacokinet 53:123-39. 2014
  4. pmc The effects of renal transplantation on circulating dendritic cells
    D A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Room Ee 563 A, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Clin Exp Immunol 140:384-93. 2005
  5. ncbi The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity
    Dennis A Hesselink
    Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, Rotterdam, The Netherlands
    Ther Drug Monit 32:387-93. 2010
  6. ncbi Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus University Medical Center, Rotterdam, The Netherlands
    Am J Transplant 5:987-94. 2005
  7. ncbi The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells
    Dennis A Hesselink
    Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Room Ee 563 A, Erasmus MC, University Medical Center Rotterdam, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Nephrol Dial Transplant 20:1868-73. 2005
  8. ncbi The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?
    Dennis A Hesselink
    Erasmus MC, Department of Internal Medicine, Room Ee 563a, Renal Transplant Unit, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Pharmacogenomics 6:323-37. 2005
  9. pmc Procalcitonin as a biomarker for severe Plasmodium falciparum disease: a critical appraisal of a semi-quantitative point-of-care test in a cohort of travellers with imported malaria
    Dennis A Hesselink
    Department of Internal Medicine, Harbour Hospital and Institute for Tropical Diseases, Haringvliet 2, 3011 TD Rotterdam, The Netherlands
    Malar J 8:206. 2009
  10. doi A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine
    Dennis A Hesselink
    Erasmus MC, Department of Internal Medicine, Division of Nephrology and Renal Transplantation, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Pharmacogenomics 9:783-9. 2008

Collaborators

Detail Information

Publications53

  1. ncbi Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, and Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus MC
    Clin Pharmacol Ther 78:317-21. 2005
  2. doi CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus MC, Rotterdam, The Netherlands
    Pharmacogenet Genomics 18:339-48. 2008
    ..We studied the influence of the CYP3A5(*)3 allele, which results in the absence of CYP3A5 protein, on tacrolimus dose and exposure, as well as the incidence of biopsy-proven acute rejection (BPAR) after renal transplantation...
  3. doi The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation
    Dennis A Hesselink
    Division of Nephrology and Renal Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Room D 427, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Clin Pharmacokinet 53:123-39. 2014
    ..The role of pharmacogenetics in tacrolimus pharmacodynamics should be explored further by the study of intra-lymphocyte and tissue tacrolimus concentrations. ..
  4. pmc The effects of renal transplantation on circulating dendritic cells
    D A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Room Ee 563 A, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Clin Exp Immunol 140:384-93. 2005
    ..Immunosuppressive drugs have important additional in vivo effects on this cell type and impair the reconstitution of the myeloid DC subset in peripheral blood after renal transplantation...
  5. ncbi The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity
    Dennis A Hesselink
    Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, Rotterdam, The Netherlands
    Ther Drug Monit 32:387-93. 2010
    ..In this paper this evidence is reviewed, with special emphasis on the role of genetic factors influencing metabolism and transportation of CNIs in both acceptor and donor...
  6. ncbi Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus University Medical Center, Rotterdam, The Netherlands
    Am J Transplant 5:987-94. 2005
    ..This finding suggests that CsA-mediated inhibition of the biliary excretion of MPAG by the Mrp2 transporter is the mechanism responsible for the interaction between CsA and MMF...
  7. ncbi The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells
    Dennis A Hesselink
    Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Room Ee 563 A, Erasmus MC, University Medical Center Rotterdam, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Nephrol Dial Transplant 20:1868-73. 2005
    ..In this study, we analysed whether this reduction resulted from CKD or from renal replacement therapy (RRT)...
  8. ncbi The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?
    Dennis A Hesselink
    Erasmus MC, Department of Internal Medicine, Room Ee 563a, Renal Transplant Unit, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Pharmacogenomics 6:323-37. 2005
    ..Ultimately, genotyping for CYP3A and ABCB1 may lead to further individualization of immunosuppressive drug therapy for the transplanted patient...
  9. pmc Procalcitonin as a biomarker for severe Plasmodium falciparum disease: a critical appraisal of a semi-quantitative point-of-care test in a cohort of travellers with imported malaria
    Dennis A Hesselink
    Department of Internal Medicine, Harbour Hospital and Institute for Tropical Diseases, Haringvliet 2, 3011 TD Rotterdam, The Netherlands
    Malar J 8:206. 2009
    ..In this study, the diagnostic accuracy of procalcitonin (PCT) for severe Plasmodium falciparum disease was assessed in a cohort of 100 consecutive travellers with various species of imported malaria...
  10. doi A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine
    Dennis A Hesselink
    Erasmus MC, Department of Internal Medicine, Division of Nephrology and Renal Transplantation, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Pharmacogenomics 9:783-9. 2008
    ....
  11. ncbi Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    Clin Pharmacol Ther 76:545-56. 2004
    ....
  12. ncbi The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy
    D A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, Dr Molewaterplein 50, 3015 DR, Rotterdam, The Netherlands
    Transpl Int 17:495-504. 2004
    ....
  13. ncbi Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus
    D A Hesselink
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Scand J Rheumatol 32:151-5. 2003
    ..To obtain insight in the acute-phase response in SLE...
  14. pmc Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Room D 412, Erasmus Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Br J Clin Pharmacol 56:327-30. 2003
    ..To evaluate the effect of corticosteroids on tacrolimus pharmacokinetics...
  15. ncbi Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
    Dennis A Hesselink
    Department of Internal Medicine, Renal Tranplant Unit, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 74:245-54. 2003
    ..The low oral bioavailability of calcineurin inhibitors is thought to result from the actions of the metabolizing enzymes cytochrome P450 (CYP) 3A4 and CYP3A5 and the multidrug efflux pump P-glycoprotein, encoded by MDR-1...
  16. ncbi The use of cyclosporine in renal transplantation
    D A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, Rotterdam, The Netherlands
    Transplant Proc 36:99S-106S. 2004
    ..Therefore, it is to be expected that in the near future CsA will remain part of the standard immunosuppressive regimen in many transplant centers...
  17. ncbi Experience with cyclosporine in endogenous uveitis posterior
    D A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, Rotterdam, The Netherlands
    Transplant Proc 36:372S-377S. 2004
    ..Hopefully such strategies will further reduce the morbidity of EPU and minimize the adverse effects associated with conventional therapies...
  18. doi Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus
    Ramin Vafadari
    Department of Internal Medicine, University Medical Center, Rotterdam, The Netherlands
    Ther Drug Monit 35:459-65. 2013
    ..Here the influence of this SNP on the biological effect of tacrolimus was studied...
  19. doi CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance
    Nilufar Pashaee
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus MC, Rotterdam, The Netherlands
    Ther Drug Monit 33:369-71. 2011
    ..The risk of long-term chronic allograft nephropathy and graft loss after kidney transplantation is increased in patients with a high intrapatient variability of tacrolimus (Tac) clearance...
  20. doi A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients
    Laure Elens
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Chem 57:1574-83. 2011
    ..Tac pharmacokinetics varies between individuals and thus complicates its use in preventing rejection after kidney transplantation. This variability might be caused by genetic polymorphisms in metabolizing enzymes...
  21. ncbi The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients
    Laure Elens
    Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    Pharmacogenet Genomics 22:373-80. 2012
    ..In the present study, the clinical impact of this single-nucleotide polymorphism was investigated in a cohort of patients receiving a CsA-based immunosuppressive regimen...
  22. pmc Hyponatraemia in imported malaria: the pathophysiological role of vasopressin
    Ewout J Hoorn
    Department of Nephrology, Erasmus MC, Rotterdam, The Netherlands
    Malar J 11:26. 2012
    ..In the pathophysiology of hyponatraemia in malaria, the relative contribution of appropriate and inappropriate arginine vasopressin (AVP) release is unknown; the trigger for inappropriate AVP release is also unknown...
  23. doi Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation
    Rachida Bouamar
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus MC, Rotterdam, The Netherlands
    Ther Drug Monit 33:178-84. 2011
    ..The authors studied the influence of these SNPs on CsA pharmacokinetics as well as on the incidence of biopsy-proven acute rejection (BPAR) and renal function after kidney transplantation...
  24. doi Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients
    Rachida Bouamar
    PharmD, Department of Hospital Pharmacy, Erasmus Medical Center, P O Box 2040, CA Rotterdam 3000, The Netherlands
    Pharmacogenet Genomics 22:399-407. 2012
    ..We investigated the association between genetic polymorphisms in ABCB1 and SLCO1B and mycophenolic acid (MPA) pharmacokinetics, and MPA-related diarrhea and leukopenia in 338 kidney transplant recipients...
  25. ncbi Genetic polymorphisms in IL-2, IL-10, TGF-β1, and IL-2RB and acute rejection in renal transplant patients
    Zhigang Chen
    Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands Department of Hospital Pharmacy, Beijing Jishuitan Hospital, Beijing, China
    Clin Transplant 28:649-55. 2014
    ..SNPs in the investigated cytokines and their receptors were not associated with the risk of AR. Genotyping patients for these SNPs is unlikely to aid the clinician in adjusting the immunosuppressive therapy for individual patients...
  26. ncbi Individualization of mycophenolate mofetil dose in renal transplant recipients
    Reinier M van Hest
    Department of Hospital Pharmacy, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Expert Opin Pharmacother 7:361-76. 2006
    ..It is expected that pharmacokinetic monitoring of mycophenolic acid will offer the most effective and feasible tool for mycophenolate mofetil dose individualization...
  27. ncbi Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus
    Laure Elens
    Departments of aClinical Chemistry bHospital Pharmacy cInternal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam dDepartment of Hospital Pharmacy, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands eLouvain Centre for Toxicology and Applied Pharmacology LTAP, Institute for Clinical and Experimental Researches IREC, Catholic University of Louvain UCL, Brussels, Belgium
    Pharmacogenet Genomics 23:649-57. 2013
    ..In the present study, we assessed the association between these variants and the risk of developing NODAT after kidney transplantation...
  28. doi Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies
    Benjamin D Noll
    Department of Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville Discipline of Pharmacology, The University of Adelaide, Adelaide Central Northern Adelaide Renal Transplant Service, The Royal Adelaide Hospital, Adelaide, Australia Departments of Internal Medicine and Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Ther Drug Monit 35:617-23. 2013
    ..This study aimed to develop a method for the quantification of TAC in small biopsy-sized samples of rat kidney and liver tissue, which could be applied to clinical biopsy samples from kidney transplant recipients...
  29. doi Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients
    Laure Elens
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands Louvain Centre for Toxicology and Applied Pharmacology LTAP Department, Universite Catholique de Louvain, Brussels, Belgium Department of Internal Medicine and Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands Department of Nephrology, Charite University, Berlin, Germany Department of Nephrology, Leiden University Medical Centre, Leiden, the Netherlands Surgery and Abdominal Transplantation Unit Cliniques universitaires St Luc, Universite Catholique de Louvain, Brussels, Belgium and Department of Nephrology, University of Leuven, Leuven, Belgium
    Ther Drug Monit 36:71-9. 2014
    ..The aim of this study was to investigate the impact of the POR*28 allele on Tac and cyclosporine A (CsA) immunosuppressive therapies...
  30. doi CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
    Laure Elens
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Rotterdam, The Netherlands
    Pharmacogenomics 14:47-62. 2013
    ..This review will summarize the current literature on phenotypes linked to this new promising CYP3A4 genetic marker SNP and discusses the potential clinical relevance...
  31. doi Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications
    Laure Elens
    Department of Clinical Chemistry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Mol Diagn Ther 16:331-45. 2012
    ..However, at present, some interesting findings can be highlighted and offer potential value to assist clinicians in decision making...
  32. pmc Hyponatraemia in imported malaria is common and associated with disease severity
    Marlies E van Wolfswinkel
    Department of Internal Medicine, Harbour Hospital and Institute for Tropical Diseases, Rotterdam, The Netherlands
    Malar J 9:140. 2010
    ..The aim of this retrospective cohort study was to determine the prevalence of hyponatraemia and its association with malaria severity in a large cohort of patients with imported malaria caused by various Plasmodium species...
  33. ncbi Clinical outcome after cyclosporine dose reduction based on C2 levels in long-term liver transplant patients
    Thanyalak Tha-In
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Dr Molewaterplein, Rotterdam, The Netherlands
    Clin Transplant 19:537-42. 2005
    ..This study investigates the effect on renal function after dose reduction based on the C2 levels in long-term liver transplant patients...
  34. doi Ischemic postconditioning in human DCD kidney transplantation is feasible and appears safe
    Eline K van den Akker
    Department of Surgery, Division of Transplant Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Transpl Int 27:226-34. 2014
    ..This is the first report of applying IPoC in human kidney transplantation. Although IPoC is feasible and appears to be safe, no benefit in terms of reduced DGF or better renal function was observed (Dutch trial registry number NTR 3117)...
  35. doi ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation
    Nauras Shuker
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, The Netherlands
    Clin Chim Acta 413:1326-37. 2012
    ..Until then, single-nucleotide polymorphisms in ABC transporter genes are not suitable to act as biomarkers for solid organ transplantation...
  36. doi Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry
    Ramin Vafadari
    Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Transplantation 93:1245-51. 2012
    ..We studied whether TAC inhibits p38 MAPK signaling in primary human T cells and ex vivo in healthy volunteers and kidney transplant recipients...
  37. pmc Copeptin does not accurately predict disease severity in imported malaria
    Marlies E van Wolfswinkel
    Department of Internal Medicine, Harbour Hospital and Institute for Tropical Diseases, Haringvliet 2, 3011 TD Rotterdam, The Netherlands
    Malar J 11:6. 2012
    ..The aim of the present study was to evaluate the performance of copeptin as a predictor of disease severity in imported malaria...
  38. pmc Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks
    Laure Elens
    Louvain Drug Research Institute LDRI, Universite Catholique de Louvain UCL, Brussels, Belgium Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam
    Br J Clin Pharmacol 77:715-28. 2014
    ..The purpose of the present review is to picture the current status of CNI pharmacogenetics and to discuss the most promising leads that have been followed so far. ..
  39. doi Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: a systematic review
    Violette M G J Gijsen
    Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Pediatr Transplant 17:205-15. 2013
    ..This conclusion warrants further research into the real risk, its risk factors, and individualization of immunosuppressant therapy...
  40. doi Protection against renal ischemia-reperfusion injury by ischemic postconditioning
    Eline K van den Akker
    Division of Transplant Surgery, Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Transplantation 95:1299-305. 2013
    ..However, thus far, no human trials investigating IPoC in transplantation have been performed. Such clinical studies are needed to establish whether a simple procedure such as IPoC can improve the outcomes of human organ transplantation...
  41. ncbi Pharmacogenetics in immunosuppressive therapy: the best thing since TDM?
    Teun van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Ther Drug Monit 26:343-6. 2004
  42. ncbi Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    T van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 87:640-1. 2010
    ..2) Typically, predose concentrations are monitored and the dose is adjusted to aim for target values that depend on immunological risk, comedication, and time since transplantation.(2)...
  43. ncbi [Kidney transplantation: more kidneys from living donors, individualised immunosuppression and better results]
    T van Gelder
    afd Inwendige Geneeskunde, Erasmus Medisch Centrum, Postbus 2040, 3000 CA Rotterdam
    Ned Tijdschr Geneeskd 147:955-9. 2003
    ..This is complicated by acute rejection episodes in 10-20% of patients. With the arrival of a number of new immunosuppressive drugs the risk of rejection might be reduced...
  44. ncbi [Twenty-five years of cyclosporin use in transplantation medicine]
    D A Hesselink
    afd Inwendige Geneeskunde, sectie Transplantatie, Erasmus Medisch Centrum, Dr Molewaterplein 50, 3015 GE Rotterdam
    Ned Tijdschr Geneeskd 147:959-64. 2003
    ..Finally, the introduction of new immunosuppressive drugs has made it possible to further reduce the dose of cyclosporin; this might eventually lead to cyclosporin-free immunosuppressive regimens...
  45. doi Efficacy and safety of exchange transfusion as an adjunct therapy for severe Plasmodium falciparum malaria in nonimmune travelers: a 10-year single-center experience with a standardized treatment protocol
    Perry J J van Genderen
    Department of Internal Medicine, Harbour Hospital and Institute for Tropical Diseases, Erasmus MC, Rotterdam, The Netherlands
    Transfusion 50:787-94. 2010
    ..Although exchange transfusion (ET) has been considered as a controversial adjunct therapy, we have not encountered any case fatality since ET was introduced as a standard adjunct therapy for patients with severe malaria...
  46. ncbi Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation
    Ozlem Tapirdamaz
    Departments of aGastroenterology and Hepatology bInternal Medicine cClinical Chemistry dSurgery eHospital Pharmacy, Clinical Pharmacology Unit Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Pharmacogenet Genomics 24:427-35. 2014
    ..We studied the influence of single-nucleotide polymorphisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 and the CNI-transporting ABCB1 on the development of CKD after LT...
  47. doi A case of primary aldosteronism revealed after renal transplantation
    Ewout J Hoorn
    Department of Internal Medicine, Erasmus Medical Center, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Nat Rev Nephrol 7:55-60. 2011
    ..Her medications included four antihypertensive agents, glucose-lowering drugs, immunosuppressants, digoxin, a coumarin derivative, and potassium chloride...
  48. pmc Procalcitonin as a Biomarker for a Bacterial Infection on Hospital Admission: A Critical Appraisal in a Cohort of Travellers with Fever after a Stay in (Sub)tropics
    Dennis A Hesselink
    Department of Internal Medicine, Harbour Hospital, Institute for Tropical Diseases, Haringvliet 2, 3011 TD Rotterdam, The Netherlands
    Interdiscip Perspect Infect Dis 2009:137609. 2009
    ..However, the diagnostic accuracy of this semiquantitative procalcitonin test for a bacterial cause of fever on admission is too poor to advocate its use in the initial clinical evaluation of fever in a setting of ill-returned travellers...
  49. doi Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samples
    Benjamin D Noll
    Department of Clinical Pharmacology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville, SA, Australia
    Ther Drug Monit 33:688-93. 2011
    ....
  50. ncbi Kinetic analysis reveals potency of CD4+ CD25bright+ regulatory T-cells in kidney transplant patients
    J H L Velthuis
    Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Transpl Immunol 18:159-65. 2007
    ..Thus, we conclude that the potency of Tregs to suppress reactivity to specific antigens should be determined by reconstitution to ongoing reactions...
  51. ncbi New rat model that phenotypically resembles autosomal recessive polycystic kidney disease
    J Nauta
    Department of Pediatrics, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Am Soc Nephrol 11:2272-84. 2000
    ....
  52. ncbi A high prevalence of culture-positive extrapulmonary tuberculosis in a large Dutch teaching hospital
    D A Hesselink
    Department of Internal Medicine, Medical Centre Rijnmond Zuid, CLARA, Olympiaweg 350, 3078 HT Rotterdam, The Netherlands
    Neth J Med 61:65-70. 2003
    ..To determine if this has resulted in altered clinical manifestations of the disease, we assessed the clinical spectrum of all TB cases diagnosed at our hospital in the period 1994 to 2000...